according to the new catalogue, 111 drugs were added to the national medical insurance, and 3 drugs were transferred out. After adjustment, the total number of drugs in the national medical insurance drug list is 2967, including 1586 kinds of western medicine and 1381 kinds of Chinese patent medicine. There are still 892 kinds of Chinese herbal pieces.
The National Medical Insurance Bureau introduced at the press conference on the adjustment of medical insurance drug list on January 18th that in this round of national medical insurance directory adjustment, the national medical insurance information platform * * * received 537 enterprise application information, involving 49 drugs, and 344 drugs passed the preliminary examination, with a passing rate of 7%. Judging from the negotiation and bidding, 147 drugs out of the catalogue participated in the negotiation and bidding, and 121 drugs were successful in negotiation or bidding, with an overall success rate of 82.3%.
"One small step harder will benefit more patients" and "Our goal is the same". On January 5-8, 223, at the medical insurance negotiation site of the Beijing National People's Congress Conference Center, The Paper noticed that many negotiators mentioned such a statement. Ten days later, with the dust of the 222 version of the medical insurance catalogue settled, the results of the 222 national medical insurance drug negotiation were officially announced.
Two COVID-19 oral drugs were successfully negotiated
Huang Xinyu, deputy director of the Department of Medical Service Management of the National Medical Insurance Bureau, introduced that the National Medical Insurance Bureau took the new crown treatment drug as the access condition of the medical insurance catalogue for the third year in a row, and two drugs, such as Azov Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance drug catalogue through negotiation. Of the 25 listed drugs involved in the tenth edition of Covid-19's infection diagnosis and treatment plan, 21 varieties have been officially included in the national medical insurance catalogue.
Previously, three COVID-19 therapeutic drugs, Azvudine tablets from real organisms, Nimatvir tablets/ritonavir tablets from Pfizer and Qingfei Paidu Granules from Institute of Clinical Basic Medicine of Chinese Academy of Traditional Chinese Medicine, participated in the national medical insurance catalogue negotiation.
according to media reports, as a result of the negotiation of azvudine, the price of the 3mg specification was reduced by about 35%, and it was included in the medical insurance at the price of 11.58 yuan/tablet. However, the new standard of azvudine is 1mg, and the price of this standard should also be lowered to 4.99 yuan/tablet according to the drug price difference specification, that is, the price of azvudine for COVID-19 treatment should be reduced from 27 yuan/bottle to about 175 yuan/bottle.
On January 8th, the person in charge of the Department of Medicine Management of the National Medical Insurance Bureau introduced that the negotiation of Azifu tablets and Qingfei Paidu granules was successful, but Paxlovid failed because the price quoted by Pfizer was too high. The person in charge said that although Paxlovid was not included in the medical insurance catalogue through negotiation, according to the recent Notice of the State Medical Insurance Bureau and relevant departments on Optimizing the Relevant Policies of Medical Insurance for Patients with Infected Diseases in novel coronavirus after the Implementation of "Class B Tube", all therapeutic drugs in the novel coronavirus Infection Diagnosis and Treatment Plan, including Paxlovid, Azvudine Tablets, Monola Wei Capsules, Dispelling Cold and Removing Dampness Granules, etc., will be temporarily paid for medical insurance until 223.
In addition, after Azvudine Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there are more than 6 drugs for treating COVID-19's symptoms such as fever and cough in the national medical insurance drug list.
Two new indications are added to domestic PD-1
The PD-1 negotiation that has attracted much attention. At present, four domestic PD-1 products have been included in medical insurance, and this medical insurance negotiation mainly focuses on adding new indications. Up to now, 13 types of PD-1 antibodies in China have been approved and entered the preliminary examination list to participate in the negotiations on increasing the indications of varieties in the catalogue.
Earlier, some media said that the above four domestic PD-1s were not included in the medical insurance, with a total of 12 indications, involving nasopharyngeal carcinoma, esophageal squamous cell carcinoma, esophageal squamous cell carcinoma, adenocarcinoma at the junction of stomach or stomach and esophagus, and non-small cell lung cancer. Among them, esophageal squamous cell carcinoma is an indication declared by four enterprises in this medical insurance catalogue negotiation.
From the published medical insurance catalogue, The Paper noted that Cinda Bio's Cindilizumab has been included in two new first-line treatment indications for gastric cancer and esophageal cancer this year. This time, Cindilizumab has become the only PD-1 inhibitor with five first-line indications included in the national medical insurance catalogue.
Professor Shen Lin, director of the Department of Gastroenterology and Oncology, Peking University Cancer Hospital, said that in recent years, immunotherapy has played an increasingly important role in the field of tumor treatment. Clinical studies have found that, on the whole, patients with esophageal cancer can benefit from immunotherapy without being limited by the expression level of PD-1 antibody, which undoubtedly gives clinicians more treatment options. Indications such as esophageal squamous cell carcinoma are included in the new national medical insurance catalogue, and the drug burden of patients will be further reduced.
The high-priced anticancer drugs failed to enter the medical insurance catalogue
It is worth mentioning that whether the "one million injections" CAR-T therapy can be successfully negotiated in this medical insurance catalogue adjustment has attracted much attention from the outside world. This year, Yaoming Junuo's Ruiqiorense injection was on the negotiation list, but it failed to enter the medical insurance catalogue through negotiation.
In addition to CAR-T therapy, ADC drugs are known as "smart biological missiles" and "magic bullets" in the field of tumor treatment. In recent years, this kind of drugs has become a research and development hotspot in the medical field.
Up to now, there are five kinds of ADC drugs * * * that have been approved for marketing in China, including Emetizumab from Roche, Vebtuximab from Takeda, Ogayizumab from Pfizer/Wyeth, Vedixituzumab from Rongchang Bio and R Wa Tozumab introduced from Genting Xinyao. In 221, vidicon was successfully negotiated into the national medical insurance catalogue; The negotiation of virtuximab failed, and Emetizumab did not enter the preliminary list.
According to the new national medical insurance catalogue, the negotiation of Emetizumab from Roche, Vebtuximab from Takeda Pharmaceutical and Vedixituzumab from Rongchang Bio was successful and appeared in the medical insurance catalogue.
7 drugs for rare diseases are included in the medical insurance catalogue
The national medical insurance bureau introduced the conference, and this time, 24 major innovative drugs made in China were included in the negotiations, and finally 2 drugs including orelbatinib were successfully negotiated. At the same time, 7 drugs for rare diseases, 22 drugs for children and 2 essential drugs were successfully listed in the catalogue, and the level of drug protection in key areas was further improved.
In p>221, seven drugs for rare diseases, including SMA therapeutic drug Nocicnatrium, were successfully negotiated into the national medical insurance, with an average price reduction of 65%. In 222, there were 19 rare disease drugs on the preliminary list, including imiglucosidase for injection of type I Gaucher's disease treatment drug under Sanofi and agarase β for injection of Fabry's disease drug; Takeda's drugs for the treatment of hereditary angioedema Ranalizumab and Gaucher's disease treatment drugs for injection Veracruz α; Roche's SMA therapeutic drug risperidone oral solution powder and so on.
According to reports, at present, China's medical insurance catalogue has included 52 kinds of drugs for rare diseases, covering 27 kinds of rare diseases. Among them, since the establishment of the National Medical Insurance Bureau, 26 kinds of drugs for rare diseases have been added to the list through negotiation, with an average decline of 53%, and the price reduction has been superimposed on medical insurance reimbursement, effectively reducing the burden on insured patients.
on January 18th, Huang Xinyu said that as long as the price of drugs for rare diseases can be negotiated, the medical insurance catalogue is very positive, and he wants to include drugs for rare diseases in the catalogue, and he has paid great attention to drugs for rare diseases in the previous review and later calculation.
According to the new medical insurance catalogue, Ranalizumab, which is a drug for treating hereditary angioedema, Ofatomuzumab, a drug for treating adult recurrent multiple sclerosis, and Risperidone oral solution powder, which is a drug for treating spinal muscular atrophy, appear in the medical insurance catalogue. In terms of domestic innovative drugs, many of them have been included in this round of negotiations. Among them, two products of Hengrui Pharma AR inhibitor Rivirutamide Tablets and Zaiding Medicine have also been included in the medical insurance drug list.